Key result
St. Jude Medical valves yield ~88% mid-term survival with low thromboembolism and no mechanical failures.
Cohort (n=228)
No
The St. Jude Medical prosthesis demonstrates excellent mid-term survival, low thromboembolic rates, and significant functional improvement in patients undergoing aortic or mitral valve replacement.
Answers are grounded in this paper and cite their sources.
Supports mid-term St. Jude prosthesis use in valve replacement; leaves open randomized comparisons to alternatives.
From April 1, 1979 to August 31, 1983, 228 patients underwent isolated aortic (AVR) (118) or mitral (MVR) (90) valve replacements with a new tilting disc valve prosthesis, the St. Jude prosthesis, at the Medical University of South Carolina. Age ranged from 6 to 84 years (mean 49.1 +/- 19.2 AVR, 44.5 +/- 16.5 MVR). Male sex predominated in the AVR group (68%) and female sex in the MVR group (68%). Thirty-five patients (16.8%) had associated coronary bypass surgery (AVR 23.7%, MVR 7.8%). There were seven deaths (3.4%) occurring during the same hospitalization (AVR: 3/118, 2.5%; MVR: 4/90, 4.4%). Follow-up is 97.6% complete and ranges from 1 to 54 months (mean 19.6 +/- 12.4). In the AVR group, nine late deaths have occurred and actuarial survival at 42 months is 86.7 +/- 3.8%. Three patients have sustained thromboembolic episodes for a linearized rate of 1.6% patient-year, and the probability of remaining free of thromboembolism at 42 months is 96.9 +/- 1.8%. The mean improvement in functional class from preoperative to postoperative is 3.1 +/- 0.7 to 1.2 +/- 0.4 (p less than 0.001). In the MVR group, there have been four late deaths, and the actuarial survival at 42 months is 89.3 +/- 3.8%. Two patients have sustained thromboembolic complications for a linearized rate of 1.2%/patient-year, and the probability of remaining free of thromboembolism at 42 months is 97.2 +/- 2%. The mean improvement in functional class from before to after surgery is 3.2 +/- 0.7 to 1.3 +/- 0.5 (p less than 0.001). There have been no thromboses of the St. Jude valve in the mitral or aortic position, no mechanical failures, and no patient has had significant valve-related hemolysis. Because of this experience, the St. Jude Medical heart valve prosthesis is our prosthesis of choice for any patient undergoing valve replacement with a mechanical prosthesis.
No takes yet. Share an insight, caveat, or question.
Crawford et al. (1984) conducted a cohort in Valvular heart disease requiring aortic or mitral valve replacement (n=228). St. Jude Medical prosthesis was evaluated on Actuarial survival at 42 months. Valve replacement with the St. Jude Medical prosthesis yielded 42-month actuarial survival of 86.7% (aortic) and 89.3% (mitral), with low thromboembolism rates and no mechanical failures.
Synapse has enriched 10 related papers. Consider them for comparative context: